OFIX stock icon

Orthofix Medical

18.56 USD
-0.17
0.91%
At close Dec 5, 4:00 PM EST
After hours
18.56
+0.00
0.00%
1 day
-0.91%
5 days
-3.43%
1 month
4.80%
3 months
8.98%
6 months
32.67%
Year to date
41.36%
1 year
77.61%
5 years
-58.78%
10 years
-37.34%
 

About: Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two main segments: global spine, including bone growth and healing therapies, spinal implants, and regenerative tissue products; and global orthopedics, providing products used in fracture repair, deformity correction, and bone reconstruction procedures. The majority of the company's sales come from the global spine segment in the United States. Orthofix distributes its products throughout North America, Europe, and several countries globally. The company provides solutions to hospitals, physicians, other healthcare providers, and patients.

Employees: 1,634

0
Funds holding %
of 6,790 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

317% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 6

15% more funds holding

Funds holding: 130 [Q2] → 149 (+19) [Q3]

9% more capital invested

Capital invested by funds: $498M [Q2] → $542M (+$43.2M) [Q3]

2% less repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 47

9.34% less ownership

Funds ownership: 100.16% [Q2] → 90.82% (-9.34%) [Q3]

20% less funds holding in top 10

Funds holding in top 10: 5 [Q2] → 4 (-1) [Q3]

97% less call options, than puts

Call options by funds: $5K | Put options by funds: $199K

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$22
19%
upside
Avg. target
$23
24%
upside
High target
$24
29%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
Roth MKM
Jason Wittes
63% 1-year accuracy
10 / 16 met price target
19%upside
$22
Buy
Reiterated
8 Nov 2024
Stifel
Mathew Blackman
64% 1-year accuracy
9 / 14 met price target
29%upside
$24
Buy
Upgraded
8 Nov 2024

Financial journalist opinion

Based on 11 articles about OFIX published over the past 30 days

Neutral
Accesswire
1 day ago
Bronstein, Gewirtz & Grossman, LLC Encourages Orthofix Medical Inc. (OFIX) Investors to Inquire about Securities Investigation
NEW YORK, NY / ACCESSWIRE / December 4, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ:OFIX). Investors who purchased Orthofix securities prior to October 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/OFIX.
Bronstein, Gewirtz & Grossman, LLC Encourages Orthofix Medical Inc. (OFIX) Investors to Inquire about Securities Investigation
Neutral
Business Wire
3 weeks ago
Orthofix to Participate in Upcoming Investor Conferences
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that Massimo Calafiore, President and Chief Executive Officer, and Julie Andrews, Chief Financial Officer, will participate in the following investor conferences: Stifel 2024 Healthcare Conference in New York, NY, November 18, 2024, fireside chat at 8:35 AM Eastern Time Stifel MedTech Madness 2024 Annual West Coast Bus Tour in Laguna Beach, CA, December 9, 2024,.
Orthofix to Participate in Upcoming Investor Conferences
Neutral
Seeking Alpha
3 weeks ago
Orthofix Medical Inc. (OFIX) Q3 2024 Earnings Call Transcript
Orthofix Medical Inc. (NASDAQ:OFIX ) Q3 2024 Results Conference Call November 7, 2024 8:30 AM ET Company Participants Julie Dewey - Chief IR and Communications Officer Massimo Calafiore - President and CEO Julie Andrews - Chief Financial Officer Conference Call Participants Mathew Blackman - Stifel Iseult McMahon - BTIG Jason Wittes - ROTH MKM Operator Good morning, and welcome to the Orthofix Third Quarter 2024 Earnings Call. I am Fran, and I'll be the operator assisting you today.
Orthofix Medical Inc. (OFIX) Q3 2024 Earnings Call Transcript
Neutral
GlobeNewsWire
3 weeks ago
OFIX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Orthofix Medical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Orthofix Medical Inc. (“Orthofix” or “the Company”) (NASDAQ: OFIX) and certain current and former officers and directors of Orthofix and SeaSpine Holdings Corporation ("SeaSpine").
OFIX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Orthofix Medical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Neutral
Accesswire
3 weeks ago
FINAL REMINDER OFIX DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Orthofix Medical Inc. Investors to Participate in the Class Action Lawsuit!
NEW YORK CITY, NY / ACCESSWIRE / November 8, 2024 / Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ:OFIX) and certain current and former officers and directors of Orthofix and SeaSpine Holdings Corporation ("SeaSpine"). Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired SeaSpine shareholders who acquired newly issued Orthofix common stock in exchange for SeaSpine shares pursuant to the January 5, 2023 stock-for-stock transaction (the "Merger") by which Orthofix merged with and acquired SeaSpine (the "Class").
FINAL REMINDER OFIX DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Orthofix Medical Inc. Investors to Participate in the Class Action Lawsuit!
Neutral
PRNewsWire
4 weeks ago
OFIX INVESTORS: OrthoFix Medical Inc. Stockholders Should Contact Robbins LLP About Joining the Pending OFIX Class Action
SAN DIEGO , Nov. 7, 2024 /PRNewswire/ -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of former SeaSpine Holdings Corporation shareholders that purchased or otherwise acquired newly issued Orthofix Medical Inc. (NASDAQ: OFIX) stock in exchange for SeaSpine shares pursuant to the January 5, 2023 stock-for-stock transaction by which Orthofix merged with and acquires SeaSpine. Orthofix is a global spine and orthopedics company that offers biologics, spinal hardware, bone growth therapies, and specialized orthopedic solutions, among other things, to healthcare professionals throughout the world.
OFIX INVESTORS: OrthoFix Medical Inc. Stockholders Should Contact Robbins LLP About Joining the Pending OFIX Class Action
Positive
Zacks Investment Research
4 weeks ago
Orthofix (OFIX) Q3 Earnings Surpass Estimates
Orthofix (OFIX) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.14 per share. This compares to earnings of $0.07 per share a year ago.
Orthofix (OFIX) Q3 Earnings Surpass Estimates
Neutral
Business Wire
4 weeks ago
Orthofix Reports Third Quarter 2024 Results, Reiterates Full-Year 2024 Financial Guidance, and Introduces New Three-Year Financial Targets
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the third quarter ended September 30, 2024, reiterated its full-year 2024 financial guidance, and introduced new three-year financial targets. Recent Highlights Third quarter 2024 net sales of $196.6 million, an increase of 7% on a reported and constant currency basis compared to third quarter 2023 U.S. Spine Fixation1 net sales growth of.
Orthofix Reports Third Quarter 2024 Results, Reiterates Full-Year 2024 Financial Guidance, and Introduces New Three-Year Financial Targets
Neutral
Business Wire
4 weeks ago
Orthofix Announces New Term Loan
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced the entry into a new credit agreement providing the Company with up to $275 million in a senior-secured term loan with a 48-month interest only period. The term loan is agented by Oxford Finance LLC (“Oxford”) and provides non-dilutive capital and financial flexibility to support Orthofix's continued focus on profitable growth. The proceeds from the initial fundi.
Orthofix Announces New Term Loan
Neutral
Accesswire
4 weeks ago
FINAL OFIX DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Orthofix Medical Inc. Investors to Join the Class Action Lawsuit!
NEW YORK CITY, NY / ACCESSWIRE / November 7, 2024 / Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ:OFIX) and certain current and former officers and directors of Orthofix and SeaSpine Holdings Corporation ("SeaSpine"). Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired SeaSpine shareholders who acquired newly issued Orthofix common stock in exchange for SeaSpine shares pursuant to the January 5, 2023 stock-for-stock transaction (the "Merger") by which Orthofix merged with and acquired SeaSpine (the "Class").
FINAL OFIX DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Orthofix Medical Inc. Investors to Join the Class Action Lawsuit!
Charts implemented using Lightweight Charts™